Biogen (HAM:IDP) Payments of Debt: €0 Mil (TTM As of Mar. 2026)


HAM:IDP Biogen Inc HAM:IDP
74 GF Score
Price €171.86
GF Value €165.52
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Biogen Payments of Debt?

Biogen HAM:IDP -1.13% 74 Payments of Debt is €0 Mil as of Mar. 2026. GuruFocus rates HAM:IDP with a GF Score™ of 74/100 and a GF Value™ of €165.52 (Fairly Valued). The stock has 7 warning signs investors should review.

Biogen's Payments of Debt for the three months ended in Mar. 2026 was €0 Mil.

Biogen's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Biogen Payments of Debt Related Terms

Biogen Payments of Debt Historical Data

* Premium members only.

The historical data trend for Biogen's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Payments of Debt Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -150.45 -946.08 -742.68 -620.75 -1,494.50

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:IDP
74GF Score
Biogen Inc HAM:IDP
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €0 Mil mean?
Biogen (HAM:IDP) has a Payments of Debt of €0 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Biogen and its competitors.
Is Biogen's Payments of Debt too high?
Biogen's current Payments of Debt is €0 Mil. Overall, Biogen has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Payments of Debt compare to OGN and AMRN?
Biogen's Payments of Debt of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Biogen and its competitors. Biogen's current Payments of Debt is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (HAM:IDP) is currently considered Fairly Valued. The stock's GF Value™ is €165.52, compared to a current price of €171.86 — trading 3.8% above its estimated fair value. The current Payments of Debt is €0 Mil. Biogen's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Biogen (HAM:IDP), the current Payments of Debt is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (HAM:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €171.86 is trading 3.8% above its estimated GF Value™ of €165.52. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for HAM:IDP:

  • Payments of Debt: €0 Mil
  • GF Value™: €165.52 vs. price of €171.86 (3.8% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
74GF Score

Get the complete analysis for HAM:IDP

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€171.86
Price
€165.52
GF Value